Interim – ASCELIA

All All press releases Regulatory press releases Financial reports

Regulatory

2023-08-18 | Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE

Regulatory

2023-05-11 | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed

Regulatory

2023-02-10 | QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023.

Regulatory

2022-11-04 | QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission

Regulatory

2022-08-18 | Half-year report 2022: Strong results from Orviglance Food Effect Study

Regulatory

2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals

Regulatory

2022-02-10 | Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agent

Regulatory

2021-11-04 | Quarterly Report Q3 2021: Oncoral – entering clinical collaboration

Regulatory

2021-08-19 | Quarterly Report Q2 2021: Preparing Oncoral for the next level

Regulatory

2021-05-12 | Quarterly Report Q1 2021: US office opened in preparation of launch

Regulatory

2021-02-16 | Quarterly Report Q4 2020: Mangoral shows high diagnostic value in new study

Regulatory

2020-11-05 | Quarterly Report Q3-2020: Raised market estimate for Mangoral and preparing for market launch

Regulatory

2020-08-20 | Quarterly Report Q2-2020: First participant in the hepatic study

Regulatory

2020-05-13 | Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE

Regulatory

2020-02-14 | 2019 year-end financial report: Sites opened for recruitment to the pivotal Phase III study SPARKLE

Regulatory

2019-08-22 | Phase III study of Mangoral to start in H2-2019